FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060636572> ?p ?o ?g. }

• W2060636572 endingPage "216" @default.
• W2060636572 startingPage "211" @default.
• W2060636572 abstract "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma. Conversely, several studies on gastric carcinoma have demonstrated that the combination of etoposide (VP-16), leucovorin (LV), and 5-FU (ELF) is efficacious and moderately toxic. UFT is a combination of uracil and tegafur (ftorafur) in a 4:1 molar ratio. It can be administered orally for several weeks, thus stimulating the effects of a continuous infusion of 5-FU. Its combination with LV increased the efficacy of UFT. We conducted a Phase II study on patients with gastric carcinoma using the combination VP-16-LV-UFT. This combination is administered mainly orally (p.o) and could yield a good response rate and low toxicity.Forty-six patients with bidimensionally measurable disease were entered into the study. Patients received VP-16 100 mg/m2 IV on Day 1 and 200 mg/ m2 p.o. on Days 2 and 3; LV 500 mg/m2 administered intravenously (i.v.) on Day 1, followed by p.o. LV 15 mg every twelve hours on Days 2 to 14. Patients also received UFT p.o. 390 mg/m2/day on Days 1 to 14. Treatment was repeated every 28 days for a minimum of 3 courses per patient. All courses were given on an outpatient basis.Four patients (9%) had a complete response, and 12 a partial response (26%) for an overall response rate of 35% (95% confidence interval: 22-51%). The median duration of response was 10 months. The median overall survival was 9 months. The main side effects were gastrointestinal. Grade 3 to 4 toxicity was encountered as follows: diarrhea in 17% of the patients, nausea/vomiting in 11%, anemia in 13%, mucositis and leukopenia in 4% each, and thrombocytopenia in 2%. One patient died of sepsis and neutropenia.VP-16-LV-UFT has an activity comparable to that of other schemes and a low incidence of side effects. Furthermore, since it is administered mainly orally, hospitalization is avoided, which makes this scheme suitable for patients with advanced gastric carcinoma." @default.
• W2060636572 created "2016-06-24" @default.
• W2060636572 creator A5000204001 @default.
• W2060636572 creator A5016485993 @default.
• W2060636572 creator A5017026317 @default.
• W2060636572 creator A5019987311 @default.
• W2060636572 creator A5026244234 @default.
• W2060636572 creator A5041333963 @default.
• W2060636572 creator A5048416170 @default.
• W2060636572 creator A5050125520 @default.
• W2060636572 creator A5085673613 @default.
• W2060636572 creator A5090038152 @default.
• W2060636572 creator A5090464803 @default.
• W2060636572 date "1996-07-15" @default.
• W2060636572 modified "2023-10-18" @default.
• W2060636572 title "Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin: A phase II study of the ONCOPAZ Cooperative Group" @default.
• W2060636572 cites W1863898801 @default.
• W2060636572 cites W1937087099 @default.
• W2060636572 cites W1940613095 @default.
• W2060636572 cites W1958288236 @default.
• W2060636572 cites W1973564709 @default.
• W2060636572 cites W1976651872 @default.
• W2060636572 cites W1983017922 @default.
• W2060636572 cites W1985862840 @default.
• W2060636572 cites W1996285570 @default.
• W2060636572 cites W2005085788 @default.
• W2060636572 cites W2020824048 @default.
• W2060636572 cites W2024912855 @default.
• W2060636572 cites W2033166317 @default.
• W2060636572 cites W2044565693 @default.
• W2060636572 cites W2087197503 @default.
• W2060636572 cites W2141121384 @default.
• W2060636572 cites W2167805334 @default.
• W2060636572 cites W2262249901 @default.
• W2060636572 cites W2288788326 @default.
• W2060636572 cites W2328993848 @default.
• W2060636572 cites W4252068621 @default.
• W2060636572 doi "https://doi.org/10.1002/(sici)1097-0142(19960715)78:2<211::aid-cncr4>3.0.co;2-o" @default.
• W2060636572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8673994" @default.
• W2060636572 hasPublicationYear "1996" @default.
• W2060636572 type Work @default.
• W2060636572 sameAs 2060636572 @default.
• W2060636572 citedByCount "24" @default.
• W2060636572 crossrefType "journal-article" @default.
• W2060636572 hasAuthorship W2060636572A5000204001 @default.
• W2060636572 hasAuthorship W2060636572A5016485993 @default.
• W2060636572 hasAuthorship W2060636572A5017026317 @default.
• W2060636572 hasAuthorship W2060636572A5019987311 @default.
• W2060636572 hasAuthorship W2060636572A5026244234 @default.
• W2060636572 hasAuthorship W2060636572A5041333963 @default.
• W2060636572 hasAuthorship W2060636572A5048416170 @default.
• W2060636572 hasAuthorship W2060636572A5050125520 @default.
• W2060636572 hasAuthorship W2060636572A5085673613 @default.
• W2060636572 hasAuthorship W2060636572A5090038152 @default.
• W2060636572 hasAuthorship W2060636572A5090464803 @default.
• W2060636572 hasConcept C121608353 @default.
• W2060636572 hasConcept C126322002 @default.
• W2060636572 hasConcept C141071460 @default.
• W2060636572 hasConcept C2776694085 @default.
• W2060636572 hasConcept C2777299880 @default.
• W2060636572 hasConcept C2777546739 @default.
• W2060636572 hasConcept C2778119113 @default.
• W2060636572 hasConcept C2780456651 @default.
• W2060636572 hasConcept C29730261 @default.
• W2060636572 hasConcept C2993220764 @default.
• W2060636572 hasConcept C31760486 @default.
• W2060636572 hasConcept C71924100 @default.
• W2060636572 hasConcept C90924648 @default.
• W2060636572 hasConceptScore W2060636572C121608353 @default.
• W2060636572 hasConceptScore W2060636572C126322002 @default.
• W2060636572 hasConceptScore W2060636572C141071460 @default.
• W2060636572 hasConceptScore W2060636572C2776694085 @default.
• W2060636572 hasConceptScore W2060636572C2777299880 @default.
• W2060636572 hasConceptScore W2060636572C2777546739 @default.
• W2060636572 hasConceptScore W2060636572C2778119113 @default.
• W2060636572 hasConceptScore W2060636572C2780456651 @default.
• W2060636572 hasConceptScore W2060636572C29730261 @default.
• W2060636572 hasConceptScore W2060636572C2993220764 @default.
• W2060636572 hasConceptScore W2060636572C31760486 @default.
• W2060636572 hasConceptScore W2060636572C71924100 @default.
• W2060636572 hasConceptScore W2060636572C90924648 @default.
• W2060636572 hasIssue "2" @default.
• W2060636572 hasLocation W20606365721 @default.
• W2060636572 hasLocation W20606365722 @default.
• W2060636572 hasOpenAccess W2060636572 @default.
• W2060636572 hasPrimaryLocation W20606365721 @default.
• W2060636572 hasRelatedWork W1978033271 @default.
• W2060636572 hasRelatedWork W1978520560 @default.
• W2060636572 hasRelatedWork W2006516489 @default.
• W2060636572 hasRelatedWork W2037286038 @default.
• W2060636572 hasRelatedWork W2086004237 @default.
• W2060636572 hasRelatedWork W2334004086 @default.
• W2060636572 hasRelatedWork W2378882726 @default.
• W2060636572 hasRelatedWork W2416954907 @default.
• W2060636572 hasRelatedWork W4229812857 @default.
• W2060636572 hasRelatedWork W88184138 @default.
• W2060636572 hasVolume "78" @default.
• W2060636572 isParatext "false" @default.

• next